Takeda and Sea Lane Biotechnologies Sign Licensing Agreement
For Use of ConCIRT Libraries and Technology


San Diego and Mountain View, CA, U.S.A., June 11, 2013 - Takeda California, Inc. (“Takeda California”), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”), and Sea Lane Biotechnologies (“Sea Lane”) jointly announced today that they have entered into a multi-year, multi-target discovery license agreement for the use of Sea Lane’s ConCIRT libraries and technology. Located in the Silicon Valley, Sea Lane is a biotech company with technologies and inventions that include the therapeutic class of entities known as Surrobodies™ and human antibody libraries. 


“The ConCIRT libraries have the potential to help advance Takeda’s research in areas where there is significant therapeutic need,” said Keith Wilson, Ph.D., President and Chief Scientific Officer of Takeda California. “We are excited about the potential of this partnership, which will provide our researchers with important tools as we strive to bring innovative medicines to people.”


Under the terms of the agreement, Sea Lane grants Takeda California access to its patented ConCIRT libraries for use in internal biotherapeutic drug discovery programs, and Takeda will be responsible for preclinical research, clinical development, and marketing of selected biotherapeutic products. In return, Sea Lane will receive an up-front payment and milestone option fees for projects initiated under the collaboration. Sea Lane stands to receive downstream milestone option payments. The agreement has an initial term of two years with a pre-negotiated option to extend.


"We are very pleased to enter into this agreement with Takeda," commented Lawrence Horowitz, M.D., Chief Executive Officer of Sea Lane. "This new therapeutic partnership with Takeda California shows the potential for innovative technologies such as our ConCIRT libraries to speed discovery and development of biotherapeutics for large pharmaceutical companies."


About Sea Lane Biotechnologies, LLC
Sea Lane Biotechnologies, LLC is a private biotechnology company focused on innovating biotherapeutic discovery with transformative technologies and platforms that are necessary to meet contemporary pharmaceutical biologic portfolio requirements, including bispecific and drug conjugated agents. Founded in 2005 in the Silicon Valley, the company is dedicated to the discovery and development of biotherapeutic drugs based upon a novel class of proteins called Surrobodies™ and the discovery of world-class antibodies for the treatment of serious human diseases, such as cancer and viral infection. Sea Lane currently has several proprietary product candidates in preclinical development. 


About Takeda California
Takeda California is Takeda's Center of Excellence and Innovation for Structure-Based Drug Discovery and Protein Therapeutics. The company combines protein x-ray crystallography, small molecule, antibody, and antibody drug-conjugate capabilities to efficiently generate potential new medicines for treating cancer, inflammatory diseases and metabolic diseases. Additional information about Takeda California is available through its affiliate Web site http://www.takedacalifornia.com.


About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, http://www.takeda.com


For further information please contact them at info@sealanebio.com.


© 2010, Sea Lane Biotechnologies, LLC.  All Rights Reserved.